A phase II study of buparlisib in relapsed or refractory thymomas.

Abu Zaid, Mohammad I; Radovich, Milan; Althouse, Sandra; Liu, Hao; Spittler, Aaron J; Solzak, Jeffrey; Badve, Sunil; Loehrer, Patrick J

Abu Zaid, Mohammad I; Radovich, Milan; Althouse, Sandra; Liu, Hao; Spittler, Aaron J; Solzak, Jeffrey; Badve, Sunil; Loehrer, Patrick J.

Afiliação

Abu Zaid MI; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Radovich M; Caris Life Science, Dallas, TX, United States.
Althouse S; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Liu H; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Spittler AJ; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Solzak J; Caris Life Science, Dallas, TX, United States.
Badve S; Department of Biostatistics, Emory University, Atlanta, GA, United States.
Loehrer PJ; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.

Front Oncol ; 12: 891383, 2022.

Article em En | MEDLINE | ID: mdl-36330484

Palavras-chave

PI3Kinase inhibitor; buparlisib; phosphoinositide-3-kinase/Akt (PI3K/Akt) pathway; thymic epithelial tumors; thymoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google